{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:24:00Z","timestamp":1792700640043,"version":"4.5.0"},"reference-count":100,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:p>Ileal bile acid transporter inhibitors (IBATi), including maralixibat and odevixibat, are a novel approach to the treatment of paediatric cholestatic liver diseases, such as Alagille syndrome (ALGS) and different forms of progressive familial intrahepatic cholestasis (PFIC). Multiple phase 3 trials have demonstrated efficacy of IBATi in alleviating pruritus and decreasing serum bile acid (sBA) in a significant subset of patients. While most clinical IBATi trials included low\u2010dose and high\u2010dose treatment, a consistent dose\u2013response effect has not been uniformly reported. This systematic review aims to assess the dose\u2013response relationship for IBATi in patients with ALGS or PFIC, based on available pruritus, sBA and (non\u2010)responder outcomes, identifying minimally effective dosage and exploring the potential for personalized dosing strategies. A systematic search was conducted across PubMed, EMBASE, Web of Science and Cochrane Library of articles, oral presentations, posters presentations and abstracts up to 29 July 2024. The analysis included 75 records, of which 68 reported sBA and 63 reported pruritus outcomes. An evident dose\u2013response relationship was not observed for either maralixibat or odevixibat in PFIC or ALGS. In the case of odevixibat, outcomes measures for patients with ALGS have only been reported for a dosage of 120\u2009\u03bcg\/kg\/day. In conclusion, the variability in therapeutic outcomes of different doses for all IBATi underscores the necessity for personalization of dosing, which may include decreasing the dosage for responders to IBATi.<\/jats:p>","DOI":"10.1002\/bcp.70277","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:54:12Z","timestamp":1759240452000},"page":"119-135","source":"Crossref","is-referenced-by-count":4,"title":["Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose\u2013response"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-6440-703X","authenticated-orcid":false,"given":"Alise D. E.","family":"de Groot","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chiad\u00f2","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen  Groningen The Netherlands"},{"name":"University of Turin  Turin Italy"},{"name":"Pediatric Gastroenterology Unit Regina Margherita Children's Hospital  Turin Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos G. W.","family":"Kosterink","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen The Netherlands"},{"name":"Research Institute of Pharmacy, Pharmacotherapy, Epidemiology &amp; Economics University of Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem S.","family":"Lexmond","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3551-1201","authenticated-orcid":false,"given":"Paola","family":"Mian","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacology University of Groningen, University Medical Center Groningen  Groningen The Netherlands"},{"name":"Department of Pediatrics Beatrix Children's Hospital, University of Groningen, University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henkjan J.","family":"Verkade","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Gastroenterology and Hepatology University of Groningen, Beatrix Children's Hospital, University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010019\u20100132\u2010z"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2017.06.001"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2007.11.010"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2017.07.024"},{"key":"e_1_2_8_6_1","volume-title":"GeneReviews\u00ae","author":"Amendola M","year":"1993"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20100041\u20101730951"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.72.121801.161712"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmg.2021.104317"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00054.2017"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13457"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001594\u2010y"},{"key":"e_1_2_8_13_1","unstructured":"Mirum Pharmaceuticals.Livmarli (maralixibat) Electronic Medicine Compendium. 2021 05\u201007\u20102024].https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/livmarli-epar-product-information_en.pdf"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010021\u201001649\u20100"},{"key":"e_1_2_8_15_1","unstructured":"Albireo Pharma.Bylvay (odevixibat) capsules for oral use: US prescribing information. 2021 05\u201007\u20102024].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/215498Orig1s000ltr.pdf"},{"key":"e_1_2_8_16_1","unstructured":"Albireo Pharma.Bylvay Electronic Medicine Compendium. 2021 05\u201007\u20102024].https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230531159442\/anx_159442_en.pdf"},{"key":"e_1_2_8_17_1","unstructured":"Mirum Pharmaceuticals.Livmarli (maralixibat) oral solution: US prescribing information. 2021 05\u201007\u20102024].https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/214662s000lbl.pdf"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2013.05.001"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31651"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1244"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1980"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00074\u20108"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100782"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4"},{"key":"e_1_2_8_25_1","unstructured":"RohatgiA.WebPlotDigitizer.https:\/\/automeris.io"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2024.111370"},{"key":"e_1_2_8_29_1","unstructured":"Mirum Pharmaceuticals.I.R.P. Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (NCT01903460). 2013 15\u201003\u20102019 [cited 2025 27 May].https:\/\/clinicaltrials.gov\/study\/NCT01903460"},{"key":"e_1_2_8_30_1","first-page":"1255A","article-title":"A long\u2010term phase 2 safety and efficacy study of the apical sodium\u2010dependent bile acid transporter inhibitor maralixibat in children with alagille syndrome: preliminary results from the imagine study","author":"Baker A","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30232-4"},{"issue":"1","key":"e_1_2_8_32_1","article-title":"Phase 2 open\u2010label efficacy and safety study of the apical sodium\u2010dependent bile acid transporter inhibitor maralixibat in children with progressive familial intrahepatic cholestasis: 48\u2010week interim efficacy analysis","volume":"66","author":"Thompson RJ","year":"2017","journal-title":"Hepatology"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/metabo12100952"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168\u20108278(20)31566\u2010X"},{"key":"e_1_2_8_35_1","first-page":"56A","article-title":"Genotype and dose\u2010dependent response to maralixibat in patients with bile salt export pump deficiency","volume":"70","author":"Thompson RJ","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_8_36_1","first-page":"783","article-title":"Serum bile acid control in long\u2010term maralixibat\u2010treated patients is associated with native liver survival in children with progressive familial intrahepatic cholestasis due to bile salt export pump deficiency","author":"Thompson R","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(21)01256\u20103"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30211-7"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2022.09.001"},{"key":"e_1_2_8_40_1","first-page":"S207","article-title":"Response to treatment with maralixibat in Alagille syndrome is associated with improved health\u2010related quality of life","author":"Kamath B","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_41_1","first-page":"1479A","article-title":"Durability of treatment effect with long\u2010term narauxibat in children with Alagille syndrome: 4\u2010year safety and efficacy results from the ICONIC study","author":"Gonzales EM","year":"2019","journal-title":"Hepatology"},{"key":"e_1_2_8_42_1","first-page":"S356","article-title":"Results of ITCH, a multi\u2010center randomized double\u2010blind placebo\u2010controlled trial of maralixibat, an ileal apical sodium\u2010dependent bile acid transporter inhibitor (ASBTi), for pruritus in alagille syndrome (ALGS)","author":"Shneider BL","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_43_1","doi-asserted-by":"crossref","unstructured":"GarciaA HsuE LinHC.Resolution of pruritus in a child with Alagille syndrome treated with maralixibat for seven years: durable response and discontinuation of other medications.2023;4(3):e335.","DOI":"10.1097\/PG9.0000000000000335"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(24)00080\u20103"},{"key":"e_1_2_8_45_1","first-page":"713","article-title":"Maralixibat improves cholestatic pruritus and bile acids in children with FIC1: data from the MARCH\u2010PFIC trial","volume":"76","author":"Miethke A","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_46_1","first-page":"S2095","article-title":"Maralixibat leads to significant improvement in cholestatic pruritus for children with progressive familial intrahepatic cholestasis due to TJP2 or MYO5B deficiency: data from MARCH\u2010PFIC trial","volume":"78","author":"Miethke AG","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_8_47_1","doi-asserted-by":"crossref","unstructured":"HorslenS MoukarzelA MiethkeAG et al.Maralixibat leads to significant improvements in cholestatic pruritus for children with progressive familial intrahepatic cholestasis without a genetic diagnosis: data from the MARCH\u2010PFIC trial.2023;78:S2096\u2010S2097.","DOI":"10.1016\/S0168-8278(23)01010-3"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)00615-3"},{"key":"e_1_2_8_49_1","doi-asserted-by":"crossref","unstructured":"MiethkeA MoukarzelA PortaG et al.Long\u2010term maintenance of response and improved liver health with maralixibat in patients with progressive familial intrahepatic cholestasis (PFIC): 2\u2010year data from the MARCH\u2010ON study.2024;79(2):E75\u2010E76.","DOI":"10.1136\/flgastro-2025-bspghan.22"},{"key":"e_1_2_8_50_1","first-page":"777","article-title":"Safety and tolerability of maralixibat in infants from 2 months of age with Alagille syndrome or progressive familial intrahepatic cholestasis: results from the RISE study","volume":"76","author":"Rosenthal P","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"5","key":"e_1_2_8_51_1","first-page":"E135","article-title":"Safety and tolerability characterization of maralixibat in infants with ALGS from 2 months of age: interm results from the RISE study","volume":"77","author":"Gonzales E","year":"2022","journal-title":"Hepatology"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep4.1992"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000502"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)01015-2"},{"key":"e_1_2_8_55_1","first-page":"868","article-title":"Gastrointestinal tolerability of maralixibat in patients with Alagille syndrome: an integrated analysis of short\u2010and long\u2010term treatment","volume":"72","author":"Kamath BM","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_56_1","first-page":"695","article-title":"Real world use of maralixibat in children with cholestasis due to Alagille syndrome: interim results of an Italian multicenter prospective study","volume":"76","author":"Matarazzo L","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"1","key":"e_1_2_8_57_1","first-page":"S435","article-title":"Real\u2010world safety experience in patients with Alagille syndrome treated with maralixibat","volume":"77","author":"Himes R","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"e_1_2_8_58_1","first-page":"763","article-title":"Significant improvement in cholestatic pruritus in patients with Alagille syndrome treated with maralixibat, an ileal bile acid transporter inhibitor: real\u2010world experience","volume":"74","author":"Gonzalez\u2010Peralta RP","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_59_1","first-page":"675","article-title":"Effects of maralixibat in children with Alagille syndrome: a French real\u2010life data analysis","volume":"76","author":"Thebaut A","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2021.101751"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0618-8278(19)30212-9"},{"key":"e_1_2_8_62_1","first-page":"S168","article-title":"The ileal bile acid transport inhibitor A4250 reduced pruritus and serum bile acid levels in children with cholestatic liver disease and pruritus: final results from a multiple\u2010dose, open\u2010label, multinational study","author":"Sturm E","year":"2017","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(22)00093\u20100"},{"key":"e_1_2_8_64_1","first-page":"S688","article-title":"Pretreatment serum bile acid parameters and predictability of response to odevixibat, an ileal bile acid transport inhibitor, in children with progressive familial intrahepatic cholestasis","author":"Verkade HJ","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_8_65_1","first-page":"A46","article-title":"L2 Efficacy and safety outcomes with odevixibat in children with progressive familial intrahepatic cholestasis due to deficiencies in multidrug resistance protein 3 (PFIC type 3) or Myosin 5B (PFIC type 6)","volume":"13","author":"\u00d6zen H","year":"2022","journal-title":"Front Gastroenterol"},{"key":"e_1_2_8_66_1","first-page":"S279","article-title":"Rapid and durable effect of odevixibat on clinical and biochemical parameters of cholestasis in children with progressive familial intrahepatic cholestasis","author":"Thompson R","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_8_67_1","first-page":"781","article-title":"Long\u2010trm safety and tolerability of odevixibat, an ileal bile acid transporter inhibitor, in children with progressive familial intrahepatic cholestasis: results from the phase 3 PEDFIC 1 and PEDFIC 2 studies","volume":"72","author":"Grammatikopoulos T","year":"2021","journal-title":"J Pediatri Gastroenterol Nutr"},{"issue":"7","key":"e_1_2_8_68_1","first-page":"S1296","article-title":"Odevixibat therapy improves clinically meaningful end points in children with progressive familial intrahepatic cholestasis: data from the PEDFIC 1 and PEDFIC 2 trials","volume":"162","author":"Thompson RJ","year":"2022","journal-title":"Gastroenterology"},{"key":"e_1_2_8_69_1","first-page":"S684","article-title":"Substantial clinical benefits with odevixibat treatment across progressive familial intrahepatic cholestasis genetic deficiencies: subgroup analysis of serum bile acids, pruritus, and safety using pooled data from the PEDFIC 1 and 2 studies","author":"Thompson RJ","year":"2021","journal-title":"J Hepatol"},{"key":"e_1_2_8_70_1","first-page":"30A","article-title":"Relationships between changes in autotaxin, pruritus, and serum bile acids after odevixibat treatment in patients with progressive familial intrahepatic cholestasis: data from a pooled analysis","author":"Gonzales EM","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_8_71_1","first-page":"S204","author":"Kamath B","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_72_1","first-page":"1159A","article-title":"Effects on serum bile acids, pruritus, and safety with up to 72 weeks of odevixibat treatment: Pooled data from the pedfic 1 and pedfic 2 studies in children with progressive familial intrahepatic cholestasis","author":"Loomes KM","year":"2021","journal-title":"Hepatology"},{"issue":"2","key":"e_1_2_8_73_1","first-page":"647","article-title":"Analysis of quality of life, hepatic biochemical markers, and sleep in patients with progressive familial intrahepatic cholestasis who had a pruritus response with odevixibat treatment","volume":"74","author":"Gupte G","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_74_1","first-page":"S49","article-title":"Relationships between decreases in serum bile acids, pruritus, and sleep disturbance scores with up to 72 weeks of odevixibat treatment in patients with progressive familial intrahepatic cholestasis","author":"Dalgic B","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_75_1","first-page":"S2104","article-title":"Odevixibat efficacy and safety across patient subgroups: an evaluation of pooled data from the PEDFIC 1 and PEDFIC 2 trials","volume":"78","author":"Sturm E","year":"2023","journal-title":"J Hepatol"},{"key":"e_1_2_8_76_1","first-page":"1164A","article-title":"Hepatic parameters, growth, and sleep with responders and nonresponders to odevixibat treatment: pooled data from the pedfic 1 and pedfic 2 studies in children with progressive familial intrahepatic cholestasis","volume":"74","author":"McKiernan P","year":"2021","journal-title":"Hepatology"},{"key":"e_1_2_8_77_1","first-page":"645","article-title":"Efficacy and safety outcomes in patients with progressive familial intrahepatic cholestasis who had an odevixibat dose escalation: pooled results from the PEDFIC 1 and PEDFIC 2 studies","author":"Grammatikopoulos T","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_78_1","first-page":"S220","article-title":"Outcomes with odevixibat in patients with progressive familial intrahepatic cholestasis by level of pruritus reduction: pooled results from the PEDFIC trials","author":"Sturm E","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_79_1","first-page":"S400","article-title":"Outcome in patients with progressive familial intrahepatic cholestasis treated with odevixibat who had medium or lower pruritus severity at baseline: pooled analysis from the PEDFIC 1 and PEDFIC 2 studies","volume":"75","author":"Loomes K","year":"2022","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_80_1","first-page":"S1548","article-title":"Effect of odevixibat in patients with progressive familial intrahepatic cholestasis type 2 with at least 1 severe mutation (BSEP3 compound heterozygotes): pooled data from the PEDFIC 1 and PEDFIC 2 studies","volume":"76","author":"Verkade HJ","year":"2022","journal-title":"Hepatology"},{"key":"e_1_2_8_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168\u20108278(22)01365\u20104"},{"key":"e_1_2_8_82_1","first-page":"A6","article-title":"Long\u2010term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results with 96 weeks or more of treatment","volume":"14","author":"Thompson R","year":"2023","journal-title":"Frontline Gastroenterol"},{"key":"e_1_2_8_83_1","article-title":"Native liver survival in odevixibat sBA responders: Data from the PEDFIC studies in patient wit progressive familial intrahepatic cholestasis","volume":"76","author":"Clemson C","year":"2022","journal-title":"Hepatology"},{"key":"e_1_2_8_84_1","first-page":"S1547","article-title":"Serum bile acid levels, pruritus scores, and growth over time in odevixibat responders: Pooled data from the PEDFIC studies in patients with progressive familial intrahepatic cholestasis","volume":"76","author":"D'Antiga L","year":"2022","journal-title":"Hepatology"},{"key":"e_1_2_8_85_1","first-page":"S438","article-title":"Changes in serum bile acids, pruritus, sleep, and quality of life with odevixibat: results by progressive familial intrahepatic cholestasis type","author":"Czubkowski P","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_86_1","first-page":"S2106","article-title":"Outcomes with odevixibat treatment in patients with Alagille syndrome: analysis of pruritus responders from the phase 3 ASSERT study","author":"Ovchinsky N","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_8_87_1","first-page":"701","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome: interim results from the open\u2010label, phase 3 ASSERT\u2010EXT study","volume":"76","author":"Ovchinsky N","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)03017-9"},{"key":"e_1_2_8_89_1","first-page":"S124","article-title":"Individual pruritus and bile acid responses over time with odevixibat treatment: pooled data from the phase 3 ASSERT and ASSERT\u2010EXT studies in patients with alagille syndrome","author":"Ovchinsky N","year":"2023","journal-title":"Hepatology"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)03068-4"},{"key":"e_1_2_8_91_1","first-page":"S1553","article-title":"Odevixibat therapy in patients with Fic1\u2010deficient progressive familial intrahepatic cholestasis and diarrhea following liver transplantation that impacted daily activities: a retrospective case series","volume":"76","author":"Vogel GF","year":"2022","journal-title":"Hepatology"},{"key":"e_1_2_8_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(23)03046-5"},{"key":"e_1_2_8_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2023.102185"},{"issue":"1","key":"e_1_2_8_94_1","first-page":"S433","article-title":"Real\u2010life experience of odevixibat treatment in patients with classic types of PFIC and with other rarer subtypes: a multicenter study","volume":"77","author":"Di Giorgio A","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_95_1","first-page":"892","article-title":"Impact of an ileal bile acid transporter inhibitor versus partial external biliary diversion in progressive familial intrahepatic cholestasis\u2014a case providing direct comparison of medical and surgical therapies","volume":"68","author":"Slavetinsky C","year":"2019","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_96_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2023.1061535"},{"key":"e_1_2_8_97_1","doi-asserted-by":"publisher","DOI":"10.3390\/children9050669"},{"key":"e_1_2_8_98_1","unstructured":"GanschowR MauckschC.Odevixibattreatment of Alagille syndrome: a case report.2023: United States p e301"},{"key":"e_1_2_8_99_1","first-page":"968","article-title":"The anti\u2010constipation medication elobixibat reduces severe hepatic pruritus in familial cholestasis","volume":"72","author":"Ohlendorf JA","year":"2021","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"e_1_2_8_100_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2023.03.226"},{"key":"e_1_2_8_101_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15543"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70277","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:35:42Z","timestamp":1769146542000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":100,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/bcp.70277"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70277","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]}}}